Peer-influenced content. Sources you trust. No registration required. This is HCN.

Journal of Clinical PathwaysASCO Updates Guideline on Early Breast Cancer Treatment

The American Society of Clinical Oncology (ASCO) published a guideline update about the selection of optimal adjuvant chemotherapy regimens and targeted therapy for early breast cancer, namely trastuzumab emtansine. In a second recommendation, the ASCO guideline addressed the use of biosimilar forms of trastuzumab—five of which have been approved by the FDA.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form